Company intelligence / Profile preview

Vanudis

Ownership: Private
Development stage: Preclinical

Overview

Vanudis is a biotechnology company focused on developing novel proprietary immunotherapeutics. Leveraging expertise in generating stable humanized antibodies and creating phage display libraries from unique donor sources, Vanudis develops innovative therapeutic classes such as CAR cell therapies, ImmunoRNAses, and innate immune-derived antibodies. The company's approach spans early preclinical research through translational steps toward clinical application. Specific pipeline programs or late-stage results are not disclosed publicly.

Therapeutic areas: OncologyOther
Modalities: Antibody therapeutics (including humanized antibody fragments)CAR cell therapeutics (CAR-T or similar cellular therapies)Immuno-ribonucleases ("ImmunoRNAses")Antibodies derived from innate immune system
Industry: Biotech

Beyond the preview

Go deeper on Vanudis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vanudis.